Gigantol 是一种具有口服活性的联苄类化合物,靶向 MYC 促进其泛素-蛋白酶体降解并抑制肺癌细胞生长,通过 SLC7A11-GPX4 轴诱导铁死亡 (Ferroptosis) 从而发挥抗肺癌活性,可恢复携带 mcr 的多重耐药菌对粘菌素的敏感性,通过抑制 JNK/cPLA2/12-LOX 炎症通路的激活改善四氯化碳诱导的肝损伤,促进睾丸间质细胞中的胆固醇代谢和孕酮生物合成,可用于肺癌、多重耐药革兰氏阴性菌感染、急性肝损伤等疾病的相关研究。
产品编号: MS-K50393 纯度: 99.79% CAS No.: 83088-28-2 分子式: C16H18O4 分子量: 274.31
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
询价
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

Gigantol 是一种具有口服活性的联苄类化合物,靶向 MYC 促进其泛素-蛋白酶体降解并抑制肺癌细胞生长,通过 SLC7A11-GPX4 轴诱导铁死亡 (Ferroptosis) 从而发挥抗肺癌活性,可恢复携带 mcr 的多重耐药菌对粘菌素的敏感性,通过抑制 JNK/cPLA2/12-LOX 炎症通路的激活改善四氯化碳诱导的肝损伤,促进睾丸间质细胞中的胆固醇代谢和孕酮生物合成,可用于肺癌、多重耐药革兰氏阴性菌感染、急性肝损伤等疾病的相关研究。

生物实验数据

生物活性 Gigantol is an orally active bibenzyl compound that targets MYC to promote its ubiquitin-proteasome degradation and inhibit lung cancer cell growth, induces ferroptosis via the SLC7A11-GPX4 axis to exert anti-lung cancer activity, restores colistin sensitivity in mcr-carrying multidrug-resistant bacteria, ameliorates carbon tetrachloride-induced liver injury by inhibiting activation of the JNK/cPLA2/12-LOX inflammatory pathway, promotes cholesterol metabolism and progesterone biosynthesis in Leydig cells, and can be used for research on lung cancer, multidrug-resistant Gram-negative bacterial infections, acute liver injury, and related diseases.
体外研究
(In Vitro)

Gigantol (0-200 μM;0-72 h) 对 H460、A549 和 H292 细胞表现出细胞毒性和具有剂量和时间依赖性的抗增殖作用。
Gigantol (0-20 μM;10 天) 可剂量依赖性地抑制 H460、A549 和 H292 细胞的集落形成能力。
Gigantol (5-20 μM;24 h) 可剂量依赖性地下调人肺癌细胞 H460、A549 和 H292 中的 MYC 蛋白表达。
Gigantol (5-20 μM;24 h) 以剂量依赖方式降低 GSK3β 的无活性磷酸化 Ser9 形式 (从而增强 GSK3β 活性),且不会改变人肺癌细胞 H460、A549 和 H292 中的总 GSK3β 水平。
Gigantol (20 μM; 15-90 min) 在与 Cycloheximide (MS-C76056) 共同孵育时,可显著降低 H460、A549 和 H292 人肺癌细胞中 MYC 蛋白的稳定性并缩短其半衰期。
Gigantol (20 μM; 1 h) 可诱导 H460、A549 和 H292 人肺癌细胞中 MYC 表达下调,增强 MYC 的泛素化水平,而蛋白酶体抑制剂 MG132 (MS-L06849) 预处理可逆转该效应。
Gigantol (50-150 μM;24 h) 可呈剂量依赖性地升高 H460 和 A549 人肺癌细胞内的 ROS 和 Fe2+ 水平,诱导细胞发生铁死亡相关的线粒体嵴丢失,降低细胞线粒体膜电位。
Gigantol (50-150 μM;24 h) 呈剂量依赖性地增强人肺癌细胞 H460 和 A549 中的脂质过氧化作用。
Gigantol (50-150 μM;24 h) 以剂量依赖的方式降低人肺癌细胞 H460 和 A549 中 SLC7A11 和 GPX4 的蛋白表达水平。
Gigantol (50-150 μM; 24 h) 可降低 H460 和 A549 人肺癌细胞的细胞外胱氨酸摄取量和细胞内半胱氨酸、GSH 水平,升高细胞内的谷氨酸、MDA 水平。
Gigantol (32 μg/mL,系列稀释处理;18 h) 可与黏菌素发挥协同作用,恢复黏菌素对携带 mcr 基因的黏菌素耐药革兰氏阴性菌 (包括 E. coli B2、Salmonella 15E343 及 K. pneumoniae 19-2-1) 的敏感性,其 FICI 值≤0.375,但不会增强黏菌素对黏菌素敏感菌株或 mcr 基因阴性菌株的活性。
Gigantol (10 μM;4 h) 可上调小鼠 MA-10 细胞中与胆固醇和类固醇生物合成/代谢相关的基因 (Star、Lss、Idi1),增加细胞中的脂滴积累,促进孕酮的生成。
Gigantol (10-100 μM; 4 h) 可升高小鼠 MA-10 睾丸间质细胞中基础 StAR 蛋白水平和 AP-1 的转录活性。
Gigantol (100 μM;4 h) 可降低小鼠 MA-10 Leydig 细胞的活力。

Cell Cytotoxicity Assay

Cell Line: H460, A549, H292 cell lines
Concentration: 0, 5, 10, 20, 50, 100, 200 μM
Incubation Time: 24 h
Result: Caused significant dose-dependent toxic effects, reducing cell viability, at 50, 100, and 200 μM in all three cell lines.
Caused no significant reduction in cell viability at 5, 10, and 20 μM in any of the tested cell lines.

Cell Proliferation Assay

Cell Line: H460, A549, H292 cell lines
Concentration: 5 μM; 10 μM; 20 μM
Incubation Time: 24, 48, 72 h
Result: Significantly reduced proliferation after 24 h in H460 and A549 cells at 20 μM. Significantly suppressed proliferation after 72 h in H460 and A549 cells at 5 and 10 μM. Significantly reduced proliferation after 48 h in H292 cells at all tested concentrations (5, 10, 20 μM).

Western Blot Analysis

Cell Line: H460, A549, H292 cell lines
Concentration: 5 μM; 10 μM; 20 μM
Incubation Time: 24 h
Result: Dose-dependently reduced MYC protein levels.
Significantly reduced MYC levels in all three cell lines at 10 and 20 μM.
Significantly reduced MYC levels in H460 and A549 cells at 5 μM.
Dose-dependently reduced the level of inactive phosphorylated Ser9 GSK3β, with no significant effect on total GSK3β levels in all three cell lines.
Significantly reduced the ratio of phosphorylated to total GSK3β in a dose-dependent manner, indicating increased GSK3β activity.

Western Blot Analysis

Cell Line: H460, A549, H292 human lung carcinoma cell lines
Concentration: 20 μM (gigantol); 5-20 μM (MG132)
Incubation Time: 1 h
Result: Significantly reduced MYC protein levels when administered alone.
Induced MYC down-regulation that was reversed by pretreatment with 5-20 μM MG132 in all three cell lines.

Western Blot Analysis

Cell Line: H460, A549
Concentration: 50-150 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent decrease in SLC7A11 and GPX4 protein expression in both H460 and A549 cells, with lower protein levels observed at higher concentrations compared to the control group.

Immunofluorescence

Cell Line: H460, A549
Concentration: 50, 100, 150 μM
Incubation Time: 24 h
Result: Increased DCFH-DA and ferroOrange
fluorescent expression.
Decrease Mito-Tracker Red CMXRos fluorescent expression.
Increased C11 BODIPY 581/591 fluorescent ratio expression.
Caused a significant decrease in GPX4 fluorescence intensity in both H460 and A549 cells, indicating reduced GPX4 protein expression compared to the control group.

ELISA Assay

Cell Line: H460, A549
Concentration: 50-150 μM
Incubation Time: 24 h
Result: Caused a concentration-dependent decrease in intracellular GPX4 content.

Real Time qPCR

Cell Line: mouse MA-10 Leydig cells
Concentration: 10 μM
Incubation Time: 4 h
Result: Increased Star gene expression in the absence of forskolin, and increased Lss gene expression. Showed a non-significant improvement in Nsdhl gene expression. Improved Idi1 gene expression in the presence of forskolin. Detected no significant changes in Fra2, Creb1, Mvd, Mvk, or Fdx1 gene expression.

Western Blot Analysis

Cell Line: mouse MA-10 Leydig cells
Concentration: 10 μM
Incubation Time: 4 h
Result: Significantly increased StAR protein levels when used alone.

ELISA Assay

Cell Line: mouse MA-10 Leydig cells
Concentration: 10 μM
Incubation Time: 4 h
Result: Increased progesterone production relative to untreated controls at 10 μM.

Cell Viability Assay

Cell Line: mouse MA-10 Leydig cells
Concentration: 1-100 μM
Incubation Time: 4 h
Result: Reduced cell viability relative to untreated controls at 100 μM.
Detected no significant changes in viability at 1 or 10 μM.
体内研究
(In Vivo)

Gigantol (30-60 mg/kg;i.p.;每日;连续 12 天) 可显著降低 BALB/c-nu 小鼠的肺肿瘤体积与重量。
Gigantol (40 mg/kg;p.o.;每日;连续 7 天) 可通过抑制 JNK/cPLA2/12-LOX 通路、减少促炎性免疫细胞的浸润与活化、恢复花生四烯酸代谢物水平,显著减轻雄性 ICR 小鼠中 CCl4 诱导的急性肝损伤与肝脏炎症。
Gigantol (40 mg/kg; i.v.; 每 12 小时 1 次,共 3 次) 可通过改善肝功能、减轻病理损伤,显著缓解雄性 C57 小鼠的肝脏缺血再灌注损伤。

Animal Model: BALB/c-nu (female, subcutaneous H460 lung cancer tumor model)
Dosage: 30 mg/kg; 60 mg/kg
Administration: i.p.; daily; 12 days
Result: Significantly inhibited tumor volume and tumor weight relative to the control group. Showed no significant differences in mouse body weight relative to the control group. Induced no apparent treatment-related toxicity in heart, liver, spleen, lung, and kidney tissues (confirmed via hematoxylin-eosin staining).
Animal Model: ICR (male, 24-26 g, acute liver injury induced by subcutaneous CCl4 injection)
Dosage: 40 mg/kg
Administration: p.o.; daily; 7 days
Result: Reversed the CCl4-induced elevation of serum ALT and AST levels.
Reduced centrilobular necrosis, swelling, steatosis, and inflammatory infiltration in liver histology.
Decreased the proportion of M1 macrophages (CD86+/F4/80+) from 38.1% to 16.3%, and the proportion of neutrophil infiltration (CD11b+/Ly6G+) from 21.7% to 9.94%.
Inhibited the CCl4-induced elevation of p-JNK/JNK protein ratio, p-cPLA2/cPLA2 protein ratio, and PLA2 mRNA expression in liver tissue.
Reversed the CCl4-induced elevation of multiple hepatic arachidonic acid metabolites, particularly significantly reducing 12-HETE levels from 6.67-fold to 2.85-fold in the control group, while also reducing the levels of 11-HETE, 8-HETE, 5,6-DHET, and 8,9-DHET.
Significantly reduced the CCl4-induced increase in the expression levels of Alox12 and Alox15 mRNA in the liver, and reduced the protein expression of platelet- and leukocyte-type 12-lipoxygenase (12-LOX) in liver tissue.
Animal Model: C57 (male, 22-25 g, hepatic ischemia-reperfusion injury induced by 70% warm hepatic ischemia for 1 hour followed by 6 hours of reperfusion)
Dosage: 40 mg/kg
Administration: i.v.; 3 times at 12-hour intervals
Result: Reduced serum ALT and AST levels.
Improved liver histopathological changes (reduced centrilobular necrosis, tumefaction, and inflammatory infiltration) compared to the ischemia-reperfusion injury group.
性状 油状物
颜色 Colorless to light yellow

化学信息

分子量 274.31
分子式 C16H18O4
CAS No. 83088-28-2

储存&溶解度

储存方式
Pure form -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 50 mg/mL (182.28 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.6455 mL18.2276 mL36.4551 mL91.1378 mL
5 mM0.7291 mL3.6455 mL7.2910 mL18.2276 mL
10 mM0.3646 mL1.8228 mL3.6455 mL9.1138 mL
15 mM0.2430 mL1.2152 mL2.4303 mL6.0759 mL
20 mM0.1823 mL0.9114 mL1.8228 mL4.5569 mL
25 mM0.1458 mL0.7291 mL1.4582 mL3.6455 mL
30 mM0.1215 mL0.6076 mL1.2152 mL3.0379 mL
40 mM0.0911 mL0.4557 mL0.9114 mL2.2784 mL
50 mM0.0729 mL0.3646 mL0.7291 mL1.8228 mL
60 mM0.0608 mL0.3038 mL0.6076 mL1.5190 mL
80 mM0.0456 mL0.2278 mL0.4557 mL1.1392 mL
100 mM0.0365 mL0.1823 mL0.3646 mL0.9114 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础